Project Grant K08CA286845
Award Date
7/15/25
Completion Date
6/30/30
Dollars Obligated
$290K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Memphis, TN 38105, USA
Similar Awards
This federal Cooperative Agreement award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), provides $481,052 in funding to the Research Institute at Nationwide Children's Hospital to develop and test new therapies for a deadly form of pediatric soft tissue cancer known as rhabdomyosarcoma (RMS). The primary goal is to establish a robust preclinical-to-clinical pipeline to rapidly advance promising treatments for RMS driven by mutations in the...
This federal Project Grant award from the Department of Health and Human Services National Institutes of Health National Cancer Institute, under the Cancer Cause and Prevention Research program (CFDA 93.393), provides $613,054 to St. Jude Children's Research Hospital Inc. to study the mechanisms by which transcription factors control different cell states in neuroblastoma, a high-risk pediatric tumor. The key objectives are to 1) interrogate how master transcription factors control the...
The National Cancer Institute (NCI) awarded a Project Grant (CFDA 93.393 - Cancer Cause and Prevention Research) worth $718,113 to St. Jude Children's Research Hospital Inc. on January 15, 2025. The grant supports research aimed at understanding the mechanisms by which the MYC oncogenes interact with core regulatory circuitry transcription factors (CRC TFs) and epigenetic modifiers, such as histone deacetylases (HDAC) and histone lysine demethylase 4 family (KDM4), to promote neuroblastoma...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $194,013 to Sanford Research, a non-profit biomedical research organization, to develop the first genetically engineered mouse models that accurately replicate key features of human high-risk rhabdomyosarcoma. The goal is to use these advanced preclinical models to explore the role of the NOTCH1 signaling pathway as both a driver and potential therapeutic target for this aggressive form...
The National Cancer Institute (NCI) awarded a Project Grant under the Cancer Research Manpower program (CFDA 93.398) to St. Jude Children's Research Hospital Inc. in the amount of $226,608 to investigate the mechanism by which a gene essential for rhabdoid tumor viability regulates chromatin function. The project aims to provide novel insights into chromatin-mediated control of transcription, the interplay between the SWI/SNF and Polycomb chromatin remodeling complexes disrupted in cancer, and...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $524,560.00 to St. Jude Children's Research Hospital Inc. to conduct research on dissecting the neomorphic functions mediated by mutant-specific structures of the SPOP protein. The research aims to characterize how cancer-associated SPOP mutations alter the protein's higher-order structural states and impact its ubiquitin-ligase functions, with the goal of informing the...
The National Cancer Institute (NCI) awarded a $788,589 Project Grant (CFDA 93.398 Cancer Research Manpower) to Children's Hospital Los Angeles (CHLA) on August 15, 2024. The grant supports research to understand how the transcription factor FOXR2 cooperates with ETS transcription factors to drive the formation of diffuse midline gliomas, a devastating type of childhood brain tumor. The research aims to elucidate the role of MAPK signaling in FOXR2-expressing gliomas and test if ETS transcription...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $441,178 to the Icahn School of Medicine at Mount Sinai to conduct research aimed at overcoming therapy resistance in pediatric leukemia driven by the NUP98-NSD1 fusion oncoprotein. The key objectives are to: Investigate the cellular and developmental dependency of NUP98-NSD1-mediated leukemic initiation across different hematopoietic stem cell populations. Characterize the...
The National Cancer Institute (NCI), through the Cancer Treatment Research Federal Grant Program (CFDA 93.395), awarded a $768,713 project grant to St. Jude Children's Research Hospital Inc. The grant, effective August 1, 2025 through July 31, 2030, will support research aimed at understanding how the histone acetyltransferase proteins EP300 and CBP control cell state plasticity and chemotherapy resistance in pediatric neuroblastoma. The project will use novel cell state reporter systems and...
This federal Project Grant award of $593,028.00 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research by the Beckman Research Institute of the City of Hope to investigate the role of IL-6/STAT3 signaling in CIC-DUX4 fusion sarcoma metastasis and immunosuppression. The goal is to define the critical role of IL-6/STAT3 signaling in tumor cell growth and metastasis, as well as in inducing tumor-associated macrophage recruitment and...